As volatility creeps into Karuna Therapeutics, Inc. (NASDAQ:KRTX), investors need to pay close attention to to the factors affecting stock today as its shares are trading 6.43% or 5.98 points up from last closing price of $93.02, reaching $99 at last check. The KRTX share price has risen in 3 of the last 5 days and is up 513.99% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -305,805 shares, and in total 137495 shares valued at $13.612 million were seen changing hands compared with 443300 shares valued at $41.236 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in KRTX stock for the next couple of days.

Karuna Therapeutics, Inc. (KRTX) shares have notched a 3-month gain of about 513.99%, but has still advanced 23.47% year to date. By comparison, the stock sank 0% over the past 12 months, while it jumped 31.89% over the 1 month. The company’s market cap is around $2.41B, with its short interest ratio standing at 0.71%.

In the current trading session for KRTX, the stock witnessed two major price actions, it rose to a high of $99.04 and was down as much as $92.87 at one point. The high recorded is very low when compared to their 52-week high which is $11.24. The 52-week high is now at -35.52 distance from current price. Their recent low of $152 represents a 771.94% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for KRTX is $123.83, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

KRTX‘s last price was up 143.75% as compared to the average trading price of 50 days recorded at $40.62 while enlarging the period to 200 trading days, the average closing price was $81.09. At present, there are 25.94 million in the total number of common shares owned by the public and among those 20.6 million shares have been available to trade. The percentage of shares being held by the company management was 20.4% while institutions stake was 48.3%. The company has generated negative returns on equity over the last 12 months (0%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the KRTX stock, there is another set of technicals that should be looked into and considered. Its 7.13% gain from moving average of $92.41 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Karuna Therapeutics, Inc. — 7 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $108.71 on shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX), which corresponds to 10.36% upside potential than its current market price of $99 and implies potential despite the recent advance in the price. However, their current target price has climbed from $88.5 a month ago and is up handily from the consensus target of $32.25 a quarter ago.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.